Cancer and bone: basic, translational and clinical

ba0001pp132 | Cancer and bone: basic, translational and clinical

The central role of the histone demethylase JHDM1D in the regulation of tumor associated genes in bone tumor-related cells

ba0001pp133 | Cancer and bone: basic, translational and clinical

Identification of tumorigenic sarcoma cancer stem cells based on high aldehyde dehydrogenase 1 activity

ba0001pp134 | Cancer and bone: basic, translational and clinical

Isolation of ALDH1^high cells by flow cytometry and investigation of the expression pattern of Wnt pathway genes in primary chordoma cell lines

ba0001pp135 | Cancer and bone: basic, translational and clinical

Anti-RANKL nanobody ALX-0141 shows sustained biomarker inhibition in a Phase I study in healthy postmenopausal Women

ba0001pp136 | Cancer and bone: basic, translational and clinical

Modulation of macrophage activation status by bisphosphonates and breast cancer cells

ba0001pp137 | Cancer and bone: basic, translational and clinical

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma

ba0001pp138 | Cancer and bone: basic, translational and clinical

New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance

ba0001pp139 | Cancer and bone: basic, translational and clinical

New PI3Kα-specific inhibitor, BYL719: therapeutic interest in osteosarcoma

ba0001pp140 | Cancer and bone: basic, translational and clinical

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and the tumor development in vivo

ba0001pp141 | Cancer and bone: basic, translational and clinical

Therapeutic interest of Imatinib Mesylate in osteosarcoma

ba0001pp142 | Cancer and bone: basic, translational and clinical

Over-expression of Smad7 in osteosarcoma cells inhibits primary tumor growth, the associated bone osteolysis and the development of lung metastasis in murine xenograft model

ba0001pp143 | Cancer and bone: basic, translational and clinical

Bone remodelling in patients with an IgM monoclonal gammopathy (Waldenstrom disease – MGUS)

ba0001pp144 | Cancer and bone: basic, translational and clinical

Selective BET bromodomains epigenetic signaling inhibition as a therapeutic strategy in primary bone tumors

ba0001pp145 | Cancer and bone: basic, translational and clinical

Synergistic anti-tumour effects on human breast cancer cells by mevalonate pathway inhibitors atorvastatin and zoledronic acid

ba0001pp146 | Cancer and bone: basic, translational and clinical

Metabolomics identifies plasma biomarkers of multiple myeloma development and progression

ba0001pp147 | Cancer and bone: basic, translational and clinical

Involvement of the co-receptor RAMP2 in the progression of breast cancer-induced osteolytic lesions

ba0001pp148 | Cancer and bone: basic, translational and clinical

Direct administration of zoledronate acid improves bone structure in local osteoporotic lesion of ovariectomized rats

ba0001pp149 | Cancer and bone: basic, translational and clinical

Cytotoxicity of picocyanobacteria strains of the genera Cyanobium on osteosarcoma cells

ba0001pp150 | Cancer and bone: basic, translational and clinical

Inhibition of osteoclastogenesis by proton pump inhibitors on co-cultures of human osteoclasts and breast cancer cells

ba0001pp151 | Cancer and bone: basic, translational and clinical

Trolox inhibits breast cancer bone metastasis and bone destruction through suppression of PGE₂ production

ba0001pp152 | Cancer and bone: basic, translational and clinical

Carcinoid tumors and DXA assessment: a study in 222 menopausal women

ba0001pp153 | Cancer and bone: basic, translational and clinical

The DXA results in 41 patients with neuroendocrine tumors: a transversal study

ba0001pp154 | Cancer and bone: basic, translational and clinical

miR-192 impairs invasion and tumor-induced osteolysis by repressing CCL2 in bone metastatic colonization

ba0001pp155 | Cancer and bone: basic, translational and clinical

Influence of sex steroids on sclerostin levels in patients with prostate cancer

ba0001pp156 | Cancer and bone: basic, translational and clinical

Vitamin D serum levels and breast cancer risk in a mediterranean population: a case–control study

ba0001pp157 | Cancer and bone: basic, translational and clinical

Bone metastatic prostate cancer cells regulate their growth via impairing osteoblast differentiation

ba0001pp158 | Cancer and bone: basic, translational and clinical

Role of receptor activity modifying proteins in skeletal regulation

ba0001pp159 | Cancer and bone: basic, translational and clinical

A novel antagonist of the canonical Wnt-signalling pathway, Sostdc1, is expressed in experimental models of myeloma and suppresses bone formation

ba0001pp160 | Cancer and bone: basic, translational and clinical

Glucose ceramide synthase inhibitors prevent osteoclast activation and limit myeloma-induced osteolytic lesions

ba0001pp161 | Cancer and bone: basic, translational and clinical

Effect of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for breast cancer: the ProBONE II Study

ba0001pp162 | Cancer and bone: basic, translational and clinical

Bone Abstracts

European Calcified Tissue Society Congress 2013

Poster Presentations

The central role of the histone demethylase JHDM1D in the regulation of tumor associated genes in bone tumor-related cells

Identification of tumorigenic sarcoma cancer stem cells based on high aldehyde dehydrogenase 1 activity

Isolation of ALDH1^high cells by flow cytometry and investigation of the expression pattern of Wnt pathway genes in primary chordoma cell lines

Anti-RANKL nanobody ALX-0141 shows sustained biomarker inhibition in a Phase I study in healthy postmenopausal Women

Modulation of macrophage activation status by bisphosphonates and breast cancer cells

Clusterin inhibition using OGX-011 synergistically enhances zoledronic acid activity in osteosarcoma

New chondrosarcoma cell lines and mouse models to study the link between chondrogenesis and chemoresistance

New PI3Kα-specific inhibitor, BYL719: therapeutic interest in osteosarcoma

NVP-BEZ235, a dual PI3K/mTOR inhibitor, inhibits osteosarcoma cell proliferation and the tumor development in vivo

Therapeutic interest of Imatinib Mesylate in osteosarcoma

Over-expression of Smad7 in osteosarcoma cells inhibits primary tumor growth, the associated bone osteolysis and the development of lung metastasis in murine xenograft model

Bone remodelling in patients with an IgM monoclonal gammopathy (Waldenstrom disease – MGUS)

Selective BET bromodomains epigenetic signaling inhibition as a therapeutic strategy in primary bone tumors

Synergistic anti-tumour effects on human breast cancer cells by mevalonate pathway inhibitors atorvastatin and zoledronic acid

Metabolomics identifies plasma biomarkers of multiple myeloma development and progression

Involvement of the co-receptor RAMP2 in the progression of breast cancer-induced osteolytic lesions

Direct administration of zoledronate acid improves bone structure in local osteoporotic lesion of ovariectomized rats

Cytotoxicity of picocyanobacteria strains of the genera Cyanobium on osteosarcoma cells

Inhibition of osteoclastogenesis by proton pump inhibitors on co-cultures of human osteoclasts and breast cancer cells

Trolox inhibits breast cancer bone metastasis and bone destruction through suppression of PGE₂ production

Carcinoid tumors and DXA assessment: a study in 222 menopausal women

The DXA results in 41 patients with neuroendocrine tumors: a transversal study

miR-192 impairs invasion and tumor-induced osteolysis by repressing CCL2 in bone metastatic colonization

Influence of sex steroids on sclerostin levels in patients with prostate cancer

Vitamin D serum levels and breast cancer risk in a mediterranean population: a case–control study

Bone metastatic prostate cancer cells regulate their growth via impairing osteoblast differentiation

Role of receptor activity modifying proteins in skeletal regulation

A novel antagonist of the canonical Wnt-signalling pathway, Sostdc1, is expressed in experimental models of myeloma and suppresses bone formation

Glucose ceramide synthase inhibitors prevent osteoclast activation and limit myeloma-induced osteolytic lesions

Effect of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for breast cancer: the ProBONE II Study

Effect of zoledronic acid on bone metabolism in patients with bone metastases from prostate or breast cancer: the ZOTECT Study

BiosciAbstracts